新斯的明甲基硫酸盐注射液市场按剂量、适应症、通路、最终用途和地区划分

2025 年新斯的明甲基硫酸盐注射液市场规模估计为 1.715 亿美元，预计到 2032 年将达到 2.334 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 4.5%。

甲基硫酸新斯的明注射液是一种胆碱酯酶抑制剂，用作重症肌无力的辅助治疗，以及在手术室和加护病房中用作非去极化神经肌肉阻断剂毒性治疗的解毒剂。该药物透过抑制乙酰胆碱酯酶而发挥作用，乙酰胆碱酯酶会分解神经肌肉接头处的神经传导物质乙酰胆碱。透过抑制这种酶，甲基硫酸新斯的明延长乙酰胆碱的作用，增加神经肌肉传递和肌肉力量。它有助于控制重症肌无力的症状，例如骨骼肌（包括四肢、身体躯干、喉咙和眼睛）无力。如果过量服用或对药物过敏，神经肌肉接头处的刺激增加会引起噁心、唾液分泌增加和肌肉痉挛等副作用。

市场动态：

老年人口的成长可能会在预测期内推动全球新斯的明甲基硫酸盐注射液市场的成长。老年人更容易患重症肌无力等神经系统疾病，这些疾病通常需要使用新斯的明甲基硫酸盐注射液治疗。不断上涨的医疗保健成本也可能在预测期内继续推动全球新斯的明甲基硫酸盐注射液市场的成长。兽医医疗保健的成长可能会在预测期内为全球新斯的明甲基硫酸盐注射液市场创造新的机会。新斯的明甲基硫酸盐注射液也用于兽医，特别是用于治疗多种动物神经肌肉疾病。新斯的明甲基硫酸盐注射液在兽医行业的使用和供应不断增加，可能会开闢新的商业性前景。

预计在预测期内，缺乏知识和诊断将阻碍全球新斯的明甲基硫酸盐注射液市场的成长。

本研究的主要特点

• 本报告对全球新斯的明甲基硫酸盐注射液市场进行了详细分析，并以 2024 年为基准年，给出了预测期 2025-2032 的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 全球新斯的明甲基硫酸盐注射液市场的关键公司是根据公司亮点、产品系列、关键亮点、业绩和策略等参数列出的。
• 从本报告中获得的见解将使负责人和企业经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
• 全球新斯的明甲基硫酸盐注射液市场报告针对该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员将透过用于分析全球新斯的明甲基硫酸盐注射液市场的各种策略矩阵来做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
• 需要使用新斯的明治疗的疾病（如重症肌无力和术后肠阻塞）的发生率正在增加。
• 缺乏知识和诊断
• 兽医学发展
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

4. 全球新斯的明甲基硫酸盐注射液市场-冠状病毒（COVID-19）大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 新斯的明甲基硫酸盐注射液市场（按剂量），2020 年至 2032 年

• 1 mg/mL
• 0.5mg/mL

6. 2020 年至 2032 年新斯的明甲基硫酸盐注射液市场（以适应症划分）

• 重症肌无力
• 缓解神经肌肉阻断

7. 全球新斯的明甲基硫酸盐注射液市场，按通路，2020 年至 2032 年

• 医院药房
• 零售药局
• 网路药局

8. 全球甲基硫酸新斯的明注射液市场（依最终用途划分），2020 年至 2032 年

• 医院
• 专科诊所
• 门诊手术中心

9. 2020 年至 2032 年各地区新斯的明甲基硫酸盐注射液市场

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 中东和非洲
  • GCC
  • 以色列
  • 其他中东地区
  • 北非
  • 中部非洲
  • 南非

第十章 竞争格局

• Baxter International Inc.
• Pfizer Inc.
• Fresenius Kabi AG
• Boehringer Ingelheim GmbH
• Mylan NV
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Sandoz（a division of Novartis）
• Accord Healthcare Inc.
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Lupin Limited

第 11 章 章节

• 调查方法
• 关于出版商

Neostigmine Methylsulfate Injection Market is estimated to be valued at USD 171.5 Mn in 2025 and is expected to reach USD 233.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032.

Neostigmine methylsulfate injection is a cholinesterase inhibitor that is used as an adjunct in the treatment of myasthenia gravis and as an antidote in the treatment of non-depolarizing neuromuscular blocking agent toxicity in the operating room or intensive care unit setting. It acts by inhibiting the acetylcholinesterase enzyme, which normally breaks down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting this enzyme, neostigmine methylsulfate prolongs the actions of acetylcholine, increasing neuromuscular transmission and muscle strength. It helps in the management of myasthenia gravis symptoms such as weakness of the skeletal muscles of the extremities, trunk, throat, and eyes. In overdose or sensitive patients, it can cause increased stimulation at the neuromuscular junction and produce side effects such as nausea, increased saliva, and muscle cramps.

Market Dynamics:

The increasing geriatric population will continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The elderly are more susceptible to neurological conditions like myasthenia gravis, which frequently needs to be treated with injections of neostigmine methylsulfate. Rising medical expenditures will also continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The growth of veterinary medicine will create new opportunities for the global neostigmine methylsulfate injection market over the forecast period. Injections of neostigmine methylsulfate are also employed in veterinary medicine, particularly for the treatment of a few neuromuscular diseases in animals. It may open up new commercial prospects to increase the use and availability of neostigmine methylsulfate injections in the veterinary industry.

Lack of knowledge and diagnosis is expected to hamper the growth of the global neostigmine methylsulfate injection market over the forecast period.

Key Features of the Study:

• This report provides an in-depth analysis of the global neostigmine methylsulfate injection market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neostigmine methylsulfate injection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Baxter International Inc., Pfizer Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Sandoz (a division of Novartis), Accord Healthcare Inc., Lannett Company, Inc., Mallinckrodt Pharmaceuticals, and Lupin Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neostigmine methylsulfate injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neostigmine methylsulfate injection market

Detailed Segmentation:

• Global Neostigmine Methylsulfate Injection Market, By Dosage:
  • 1 mg/mL
  • 0.5 mg/mL
• Global Neostigmine Methylsulfate Injection Market, By Indications:
  • Myasthenia Gravis
  • Reversal of Neuromuscular Blockade
• Global Neostigmine Methylsulfate Injection Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Neostigmine Methylsulfate Injection Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
• Global Neostigmine Methylsulfate Injection Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profile:
  • Baxter International Inc.
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Boehringer Ingelheim GmbH
  • Mylan N.V.
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz (a division of Novartis)
  • Accord Healthcare Inc.
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Lupin Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Neostigmine Methylsulfate Injection Market, By Dosage
  • Neostigmine Methylsulfate Injection Market, By Indication
  • Neostigmine Methylsulfate Injection Market, By Distribution Channel
  • Neostigmine Methylsulfate Injection Market, By End User
  • Neostigmine Methylsulfate Injection Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine
  • Restraints
• Lack of knowledge and diagnosis
  • Opportunities
• Growth of veterinary medicine
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Neostigmine Methylsulfate Injection Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Neostigmine Methylsulfate Injection Market, By Dosage, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 1 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• 0.5 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Neostigmine Methylsulfate Injection Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Myasthenia Gravis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Reversal of Neuromuscular Blockade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Neostigmine Methylsulfate Injection Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Neostigmine Methylsulfate Injection Market, By End User, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Global Neostigmine Methylsulfate Injection Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Fresenius Kabi AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sandoz (a division of Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Accord Healthcare Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lannett Company, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us